Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Return on Sales (2019 - 2025)

Historic Return on Sales for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to 81.93%.

  • Bioadaptives' Return on Sales fell 605000.0% to 81.93% in Q3 2025 from the same period last year, while for Sep 2025 it was 145.62%, marking a year-over-year decrease of 1241900.0%. This contributed to the annual value of 54.78% for FY2024, which is 410700.0% down from last year.
  • According to the latest figures from Q3 2025, Bioadaptives' Return on Sales is 81.93%, which was down 605000.0% from 49.06% recorded in Q2 2025.
  • Bioadaptives' 5-year Return on Sales high stood at 6.46% for Q3 2021, and its period low was 1224.44% during Q1 2025.
  • Moreover, its 5-year median value for Return on Sales was 50.59% (2022), whereas its average is 118.0%.
  • Data for Bioadaptives' Return on Sales shows a peak YoY increase of 2220800bps (in 2025) and a maximum YoY decrease of -12157300bps (in 2025) over the last 5 years.
  • Quarter analysis of 5 years shows Bioadaptives' Return on Sales stood at 80.07% in 2021, then soared by 63bps to 29.33% in 2022, then surged by 52bps to 13.99% in 2023, then plummeted by -279bps to 53.05% in 2024, then plummeted by -54bps to 81.93% in 2025.
  • Its Return on Sales was 81.93% in Q3 2025, compared to 49.06% in Q2 2025 and 1224.44% in Q1 2025.